FDA approves first ketamine-based antidepressant

Depression is the leading cause of disability worldwide, affecting more than 300 million people of all ages around the world. The most commonly used antidepressant medications are called selective serotonin reuptake inhibitors (SSRIs). Only about  one third of people with major depressive disorder achieve remission after treatment with SSRIs. When the first medication doesn’t work, the next steps are usually to switch to or add another … Continue reading FDA approves first ketamine-based antidepressant

Down, but not out: Developments in depression research

by Emily Ricq Depression affects 15 million Americans and is characterized by debilitating feelings of sadness or emptiness that interfere with the ability to lead and enjoy life [1]. The substantial personal and public health burden imposed by depression has motivated decades of intensive research by scientists, clinicians, therapists, and pharmaceutical companies alike, yet the biology underlying the cause (or causes) of the disease and … Continue reading Down, but not out: Developments in depression research